Tresiba gains FDA approval for use in children and adolescents

Children and adolescents age 1 and up now have another option in basal insulin. On December 19, 2016, Novo Nordisk announced that the FDA approved an expanded indication for Tresiba (insulin degludec injection 100 U/mL, 200 U/mL).